FDA Evaluates Peptides for Section 503A Compounding List Lance Liberti, MBA, BCPA posted on the topic LinkedIn The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with RFK Jr. & claimed regenerative peptides like BPC 157 The Niche